0GHZ Stock Chart & Stats
kr15.14
kr0.00(0.00%)
At close: 4:00 PM EDT
kr15.14
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr9.14 - kr31.90
Previous CloseN/A
Volume0.00
Average Volume (3M)1.75K
Market Cap
kr496.93M
Enterprise Valuekr645.43M
Total Cash (Recent Filing)kr179.91M
Total Debt (Recent Filing)kr147.30M
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding47,416,573
10 Day Avg. Volume1,709
30 Day Avg. Volume1,750
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.2
Revenue Forecast (FY)kr19.00M
Bulls Say, Bears Say
Bulls Say
HyNap Formulation PlatformThe HyNap platform is designed to improve established medicines rather than discover entirely new compounds, which can support differentiated product candidates and potentially reduce development complexity. Its focus on bioavailability and food-effect benefits may create licensing appeal in specialty pharmaceuticals.
Moderate LeverageSubstantial equity relative to debt gives Xspray a comparatively moderate leverage profile for an early-stage biotech. This provides more financial flexibility than a highly indebted structure, although continued losses and cash needs could still erode that position over time.
Improving Loss TrendThe reduction in net losses from the 2024 trough indicates some improvement in financial performance, even though profitability has not been reached. If sustained, lower losses could extend the company’s operational runway and reduce the pace at which external funding is required.
Bears Say
No Commercial RevenueXspray has not yet demonstrated recurring commercial revenue, leaving its business model dependent on advancing candidates toward approval and monetization. Persistent losses indicate that the technology platform has not yet translated into self-funding operations or durable earnings power.
Persistent Cash BurnSustained negative operating and free cash flow means Xspray consumes cash while developing its products, rather than funding operations internally. This dependence on financing can constrain strategic flexibility and increases execution risk if commercialization or partnership milestones take longer than expected.
Increasing Leverage And Negative ReturnsAlthough leverage remains moderate, its material increase from earlier years alongside consistently negative return on equity shows that capital is not yet generating shareholder returns. Continued losses could weaken the balance sheet and make future funding increasingly important to sustain development.
Xspray Pharma AB News
0GHZ FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest share price was kr9.14 and its highest was kr31.90 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr496.93M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 6 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -kr0.868 earnings per share for the quarter.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr0.868 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in GB:0GHZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Camurus AB
―
Vicore Pharma Holding AB
―
Xbrane Biopharma AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―